195 related articles for article (PubMed ID: 29344648)
1. Effect of midkine on gemcitabine resistance in biliary tract cancer.
Lu Y; Yan B; Guo H; Qiu L; Sun X; Wang X; Shi Q; Bao Y
Int J Mol Med; 2018 Apr; 41(4):2003-2011. PubMed ID: 29344648
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Okumura Y; Noda T; Eguchi H; Sakamoto T; Iwagami Y; Yamada D; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Ann Surg Oncol; 2018 Nov; 25(12):3728-3737. PubMed ID: 30105440
[TBL] [Abstract][Full Text] [Related]
3. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.
Yamada D; Kobayashi S; Wada H; Kawamoto K; Marubashi S; Eguchi H; Ishii H; Nagano H; Doki Y; Mori M
Eur J Cancer; 2013 May; 49(7):1725-40. PubMed ID: 23298711
[TBL] [Abstract][Full Text] [Related]
4. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
7. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Kim J; Kim H; Lee JC; Kim JW; Paik WH; Lee SH; Hwang JH; Ryu JK; Kim YT
PLoS One; 2018; 13(12):e0209104. PubMed ID: 30557411
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
[TBL] [Abstract][Full Text] [Related]
9. A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Sakamoto T; Kobayashi S; Yamada D; Nagano H; Tomokuni A; Tomimaru Y; Noda T; Gotoh K; Asaoka T; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
PLoS One; 2016; 11(1):e0145985. PubMed ID: 26726879
[TBL] [Abstract][Full Text] [Related]
10. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.
Wu CE; Pan YR; Yeh CN; Lunec J
Biomolecules; 2020 Oct; 10(11):. PubMed ID: 33113997
[TBL] [Abstract][Full Text] [Related]
11. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
12. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
Ojima H; Yoshikawa D; Ino Y; Shimizu H; Miyamoto M; Kokubu A; Hiraoka N; Morofuji N; Kondo T; Onaya H; Okusaka T; Shimada K; Sakamoto Y; Esaki M; Nara S; Kosuge T; Hirohashi S; Kanai Y; Shibata T
Cancer Sci; 2010 Apr; 101(4):882-8. PubMed ID: 20088962
[TBL] [Abstract][Full Text] [Related]
13. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
Ueno G; Iwagami Y; Kobayashi S; Mitsufuji S; Yamada D; Tomimaru Y; Akita H; Asaoka T; Noda T; Gotoh K; Mori M; Doki Y; Eguchi H
Ann Surg Oncol; 2022 May; 29(5):2899-2909. PubMed ID: 34994902
[TBL] [Abstract][Full Text] [Related]
14. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Pignochino Y; Sarotto I; Peraldo-Neia C; Penachioni JY; Cavalloni G; Migliardi G; Casorzo L; Chiorino G; Risio M; Bardelli A; Aglietta M; Leone F
BMC Cancer; 2010 Nov; 10():631. PubMed ID: 21087480
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines.
Kinoshita M; Kobayashi S; Gotoh K; Kubo M; Hayashi K; Iwagami Y; Yamada D; Akita H; Noda T; Asaoka T; Takeda Y; Tanemura M; Eguchi H; Urakawa S; Goto K; Maekawa K; Wada H; Mori M; Doki Y
Dig Dis Sci; 2020 Oct; 65(10):2937-2948. PubMed ID: 31853779
[TBL] [Abstract][Full Text] [Related]
16. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
[TBL] [Abstract][Full Text] [Related]
17. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Guo Q; Qin W
J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
Carotenuto P; Hedayat S; Fassan M; Cardinale V; Lampis A; Guzzardo V; Vicentini C; Scarpa A; Cascione L; Costantini D; Carpino G; Alvaro D; Ghidini M; Trevisani F; Te Poele R; Salati M; Ventura S; Vlachogiannis G; Hahne JC; Boulter L; Forbes SJ; Guest RV; Cillo U; Said-Huntingford I; Begum R; Smyth E; Michalarea V; Cunningham D; Rimassa L; Santoro A; Roncalli M; Kirkin V; Clarke P; Workman P; Valeri N; Braconi C
Hepatology; 2020 Sep; 72(3):982-996. PubMed ID: 31879968
[TBL] [Abstract][Full Text] [Related]
19. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Wolf S; Lorenz J; Mössner J; Wiedmann M
World J Gastroenterol; 2010 Jan; 16(2):156-66. PubMed ID: 20066734
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Wang Z; Li Y; Kong D; Banerjee S; Ahmad A; Azmi AS; Ali S; Abbruzzese JL; Gallick GE; Sarkar FH
Cancer Res; 2009 Mar; 69(6):2400-7. PubMed ID: 19276344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
